Geleen, September 17, 2026

赫伦，2026年9月17日

Matisse Pharmaceuticals B.V., a clinical stage company developing isupartob sodium for the treatment of sepsis, today announced the successful completion of its Series A financing round.

马蒂斯制药公司（Matisse Pharmaceuticals B.V.）是一家处于临床阶段的公司，正在开发用于脓毒症治疗的异帕妥布钠（isupartob sodium）。该公司今天宣布其A轮融资成功完成。

The €14 million financing round was led by the company's existing & new shareholder base. This included participation from a group of institutional investors which included Brightlands Venture Partners & LIOF, private investors and management, further strengthening Matisse's long-term investor syndicate.

本轮1400万欧元的融资由公司现有及新股东共同领投。其中包括Brightlands Venture Partners和LIOF等机构投资者群体、私人投资者以及管理层的参与，进一步巩固了Matisse的长期投资者联盟。

The proceeds will primarily be used to execute the Phase 2 clinical trial of isupartob sodium, a key value-inflection milestone for the company, while supporting regulatory, manufacturing and operational activities. The financing reflects continued confidence in Matisse's differentiated therapeutic approach and the significant unmet medical need addressed by isupartob..

所得款项将主要用于推进isupartob钠的二期临床试验，这是公司一个关键的价值转折里程碑，同时支持监管、制造和运营活动。此次融资反映了市场对Matisse差异化治疗方法的持续信心，以及isupartob所解决的重大未满足医疗需求。

'This financing represents an important milestone for Matisse,' said Marcel Jacobs, Chief Executive Officer of Matisse Pharmaceuticals. 'We are grateful for the continued commitment of our existing shareholders and are pleased to welcome new investors who share our long-term vision. Their support enables us to focus on what matters most: Successfully completing our Phase 2 clinical trial in sepsis patients and generating the clinical data needed to unlock the next stage of the company's development.

“此次融资对马蒂斯公司而言是一个重要的里程碑，”马蒂斯制药公司首席执行官马塞尔·雅各布斯表示。“我们感谢现有股东的持续支持，并很高兴欢迎认同我们长期愿景的新投资者加入。他们的支持使我们能够专注于最关键的任务：顺利完成针对脓毒症患者的二期临床试验，并生成推动公司进入下一发展阶段所需的临床数据。”

We believe this positions Matisse to create significant value for patients, partners and shareholders alike.'.

我们相信，这将使马蒂斯能够为患者、合作伙伴和股东创造重大价值。

Matisse Pharmaceuticals structured the financing as a company-led round, allowing it to broaden its shareholder base with long-term investors while maintaining strategic flexibility as it advances toward its next clinical milestones.

马蒂斯制药公司将此次融资安排为由公司主导的轮次，使其在推进至下一个临床里程碑的过程中，既能通过引入长期投资者来扩大股东基础，又能保持战略灵活性。

Completion of the Phase 2 study is expected to provide important data regarding the safety, tolerability and clinical activity of isupartob in sepsis patients and will inform Matisse's subsequent development strategy.

预计二期研究的完成将提供有关isupartob在脓毒症患者中的安全性、耐受性和临床活性的重要数据，并将为Matisse的后续开发策略提供依据。

About Sepsis and the unmet medical need

关于脓毒症及未满足的医疗需求

According to the WHO, sepsis is one of the leading causes of death worldwide. Currently, there is no treatment effective against sepsis approved by regulatory authorities. Of the 49 million patients globally suffering from sepsis every year, more than 20% die. Approximately 40% of the sepsis cases are children under the age of 5, with close to 3 million children dying from sepsis each year.

据世界卫生组织称，脓毒症是全球主要的死亡原因之一。目前，尚无监管机构批准的针对脓毒症的有效治疗方法。在全球每年遭受脓毒症困扰的4,900万患者中，超过20%的患者死亡。大约40%的脓毒症病例是5岁以下儿童，每年有近300万儿童死于脓毒症。

According to a study by Buchman et al. (2020), published in Critical Care Medicine, sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone. .

根据Buchman等人（2020年）发表在《重症监护医学》上的一项研究，脓毒症是住院死亡的最常见原因，仅在美国每年就造成超过620亿美元的损失。

Sepsis remains one of the most significant unmet medical needs in critical care medicine and despite decades of research, no targeted therapies have been successfully developed to address the dysregulated host response that drives organ failure and death in sepsis.

脓毒症仍然是重症监护医学中最为突出的未满足医疗需求之一。尽管经过数十年的研究，尚未成功开发出针对脓毒症中导致器官衰竭和死亡的失调宿主反应的靶向疗法。

Isupartob mechanism of action

异舒托巴的作用机制

Isupartob is a novel therapeutic designed to neutralize extracellular histones, key mediators of endothelial injury, inflammation and organ failure in sepsis.

Isupartob 是一种新型治疗药物，旨在中和细胞外组蛋白，这些组蛋白是脓毒症中内皮损伤、炎症和器官衰竭的关键介质。

In sepsis patients the innate immune system releases proteins known as histones into the bloodstream. These histones are toxic to cell membranes leading to cell death and release of additional histones. The result is a self-enforcing cascade that drives organ failure. The highly negatively charged isupartob binds to these positively charged extracellular histones.

在脓毒症患者中，先天免疫系统会将称为组蛋白的蛋白质释放到血液中。这些组蛋白对细胞膜具有毒性，导致细胞死亡并释放更多的组蛋白。结果形成一个自我强化的级联反应，进而引发器官衰竭。带有高度负电荷的isupartob能够与这些带正电荷的胞外组蛋白结合。

By targeting this upstream mechanism in the inflammatory cascade, the therapy aims to reduce mortality and improve outcomes in critically ill patients..

该疗法通过靶向炎症级联反应中的这一上游机制，旨在降低危重患者的死亡率并改善其预后。

About Matisse Pharmaceuticals

关于 Matisse Pharmaceuticals

Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. The company develops safe and innovative therapies for disease indications characterized by elevated levels of circulating cytotoxic histones, including sepsis.

马蒂斯制药公司（Matisse Pharmaceuticals B.V.）于2014年在荷兰赫伦成立。该公司致力于开发安全且创新的治疗方案，针对以循环中毒性组蛋白水平升高为特征的疾病适应症，包括败血症。

For more information, please contact:

如需更多信息，请联系：

Marcel Jacobs, CEO

马塞尔·雅各布斯，首席执行官

(T) +31 6 575 27 541

电话：+31 6 575 27 541

(E) m.jacobs@matissepharmaceuticals.com

(E) m.jacobs@matissepharmaceuticals.com

(W) www.matissepharmaceuticals.com

（女）www.matissepharmaceuticals.com

Attachment

附件

20260917 (NL) Matisse rondt Series A-financieringsronde af (Final)

20260917（荷兰）Matisse 完成 A 轮融资（最终版）